The workforce reduction is a direct consequence of AlloVir's decision to discontinue significant clinical studies, indicating a major strategic shift and potential issues with its product pipeline. This could lead to investor concern about the company's future prospects and financial stability, likely resulting in a negative short-term impact on the stock price. The high restructuring costs will also affect the company's financials, although the long-term effects may include reduced operational costs.